Savara Pharmaceuticals

Savara Pharmaceuticals

Savara Pharmaceuticals

Savara Pharmaceuticals develops an inhaled antibiotic for MRSA infection inCystic Fibrosis
Type
B2c
Founded
2007
Raised
$103.9M
Follow us
Alexa global traffic share
Latest funding Show all
$47,000,000
Post-IPO equity - 2017
$15,000,000
Debt financing - 2017
Silicon Valley Bank
Team Size
2
Employees
$15,000,000 Debt financing
texastechpulse

Savara Gets $15M In Debt Funding From SVB

Xconomy

Inhaled-Drug Maker Savara Buys European Biotech With Two Candidates

Health
$20,000,000 Venture capital (Series C)
FinSMEs , Xconomy

Savara Pharmaceuticals Closes $20M Series C Financing

Health Funding